| 급성 편두통 발작에 대한 피하용 Sumatriptan의 임상적 효용성에 관한? 연구 |
| 주재형, 이상찬, 성상민, 정대수, 박규현 |
| 부산대학교 신경과 |
| The Clinical Efficacy of Subcutaneous Sumatriptan (Imigran ) for ?Acute Treatment of Migraine
|
| Jae Hyung Joo, M.D., Sang Chan Lee, M.D., Sang Min Sung, M.D., Dae Soo Jung, M.D., Kyu Hyun Park, M.D. |
| Department of Neurology, Pusan National University Hospital |
|
|
|
|
| Abstract |
|
Sumatripan is a selective agonist at the 5-hydroxytryptamine (5HT,) -like receptor. An open, uncontrolled study was conducted to evaluate the therapeutic response of Korean patients to sumatriptan 6mg using an autoinjector for acute migraine attacks. 38 migraineurs were diagnosed by neurologists and included in the study. However, 7 patients were withdrawn as they failed to have an attack and one more or one additional patient was withdrawn due to syncope immediately after the first injection Patients recorded details of each attack and the response to treatment in a diary card. A total of 64 attacks in 30 patients were finally 'mcluded to evaluate the efficacy of treatment.
Sumatriptan was very effective at relieving acute migraine attacks of various severity
and the associated symptoms (nausea, vomiting, photophobia and phonophobia). Within
two and a half hours after injection, 97% (62/64) showed a significant improvement of
symptoms from moderate/severe at baseline to mild/none after treatment. There is no
significant statistical difference of response of treatment about each type of migraine
(classic migraine vs common migraine, chisquare test, ;? = 3. 84, p = 0. 650). Adverse
events occurred 46% (30/65) of attacks. These were usually mild and transient, the
most common being chest discomfort, pain at site of injection, nausea/vomiting, neck
pain/stiffness, dizziness, sensation of weakness and tingling. In conclusion, sumatriptan
taken by subcutaneous injection using an automjector was highly effective, fast acting
and well tolerated in the treatment of acute migraine. |
|
PDF Links
Full text via DOI
Download Citation
